1318 related articles for article (PubMed ID: 25319867)
1. Translational biology of osteosarcoma.
Kansara M; Teng MW; Smyth MJ; Thomas DM
Nat Rev Cancer; 2014 Nov; 14(11):722-35. PubMed ID: 25319867
[TBL] [Abstract][Full Text] [Related]
2. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
3. Genomics and the Immune Landscape of Osteosarcoma.
Wu CC; Livingston JA
Adv Exp Med Biol; 2020; 1258():21-36. PubMed ID: 32767232
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in osteosarcoma.
Botter SM; Neri D; Fuchs B
Curr Opin Pharmacol; 2014 Jun; 16():15-23. PubMed ID: 24632219
[TBL] [Abstract][Full Text] [Related]
5. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
6. Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma.
Brard C; Piperno-Neumann S; Delaye J; Brugières L; Hampson LV; Le Teuff G; Le Deley MC; Gaspar N
BMJ Open; 2019 May; 9(5):e025877. PubMed ID: 31110092
[TBL] [Abstract][Full Text] [Related]
7. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis.
Song HJ; Lee EK; Lee JA; Kim HL; Jang KW
Tumour Biol; 2014 Sep; 35(9):8771-9. PubMed ID: 24874050
[TBL] [Abstract][Full Text] [Related]
8. The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.
Bellini G; Di Pinto D; Tortora C; Manzo I; Punzo F; Casale F; Rossi F
Curr Cancer Drug Targets; 2017; 17(7):650-656. PubMed ID: 27993113
[TBL] [Abstract][Full Text] [Related]
9. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
10. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
11. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies.
Schott C; Shah AT; Sweet-Cordero EA
Adv Exp Med Biol; 2020; 1258():1-19. PubMed ID: 32767231
[TBL] [Abstract][Full Text] [Related]
12. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
Meyers PA
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
[TBL] [Abstract][Full Text] [Related]
13. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
14. New paradigms for therapy for osteosarcoma.
Nagarajan R; Clohisy D; Weigel B
Curr Oncol Rep; 2005 Nov; 7(6):410-4. PubMed ID: 16221377
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
16. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.
Johal S; Ralston S; Knight C
Value Health; 2013 Dec; 16(8):1123-32. PubMed ID: 24326165
[TBL] [Abstract][Full Text] [Related]
17. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
18. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
19. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I; Verrecchia F; Crenn V; Redini F; Trichet V
Cells; 2020 Apr; 9(4):. PubMed ID: 32326444
[TBL] [Abstract][Full Text] [Related]
20. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
